The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).
The second-generation anticancer agent with a dual-mechanism vascular disrupting feature integrates vascular disrupting activity and direct cytotoxicity. With the issuance of orphan drug designation, the company gains market
According to the study data, the AB103 administered patients demonstrated a meaningful improvement across multiple endpoints compared to placebo. The University of Washington Harborview Medical Center professor of
Under the collaboration, Ablynx will provide access to novel Nanobodies, generated using proprietary technology platform, and Algeta will provide access to chelation and conjugation technologies, as well as
The cyclophilin inhibitors drugs include CicloMulsion and NeuroSTAT which are intended to treat heart reperfusion injury after stenting and traumatic brain injury respectively. Both the products prevent the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
